The addition of neoadjuvant and adjuvant pembrolizumab to standard chemotherapy and surgery may improve outcomes in patients with early-stage non-small cell lung cancer
Bookmark1. At 24 months, more participants in the pembrolizumab group were alive without an event,...
Read More